Ligand Pharmaceuticals (LGND), GSK's (GSK) promacta approved - Report
Ligand Pharmaceuticals (NASDAQ: LGND), GSK's (NYSE: GSK) promacta approved for treatment of low blood platelet counts in HepC patients, Adam Feuerstein reports.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Express Scripts (ESRX) weekly volatility increases into Q2 and outlook
- Impinj (PI) Continues Post-IPO Ramp
- Juniper (JNPR) July weekly volatility elevated at 85 into Q2 and outlook
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!